Drug Overview: Tecentriq

  • ID: 4462130
  • Drug Pipelines
  • 82 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells and some tumor cells. PD-L1 binds to programmed death-1 (PD-1) co-inhibitory receptors which are expressed on the surface of T cells after T-cell activation. The receptor ligand interaction produces inhibitory signals which regulate T-cell activation and promote immune tolerance, which favors tumor progression. By blocking the PD-L1/PD-1 interaction, Tecentriq enables T-cell activation and allows the immune system to mount a more effective anti-tumor response.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Tecentriq: Prostate cancer
Tecentriq: Colorectal cancer (CRC)
Tecentriq: Ovarian cancer
Tecentriq: Bladder cancer
Tecentriq: Renal cell cancer (RCC)
Tecentriq: Non-small cell lung cancer (NSCLC)
atezolizumab: Breast cancer: triple-negative

List of Figures
Figure 1: Tecentriq for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of Tecentriq for prostate cancer
Figure 3: Drug assessment summary of Tecentriq for prostate cancer
Figure 4: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Tecentriq for colorectal cancer - SWOT analysis
Figure 6: Drug assessment summary of Tecentriq for colorectal cancer
Figure 7: Drug assessment summary of Tecentriq for colorectal cancer
Figure 8: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
Figure 9: Tecentriq for ovarian cancer - SWOT analysis
Figure 10: Drug assessment of Tecentriq for ovarian cancer
Figure 11: Drug assessment of Tecentriq for ovarian cancer
Figure 12: Tecentriq for urothelial bladder cancer - SWOT analysis
Figure 13: Drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 14: Drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 15: Tecentriq for renal cell cancer - SWOT analysis
Figure 16: Drug assessment summary of Tecentriq for renal cell cancer
Figure 17: Drug assessment summary of Tecentriq for renal cell cancer
Figure 18: Tecentriq for non-small cell lung cancer - SWOT analysis
Figure 19: Drug assessment summary for Tecentriq in non-small cell lung cancer
Figure 20: Drug assessment summary for Tecentriq in non-small cell lung cancer
Figure 21: Atezolizumab for triple-negative breast cancer - SWOT analysis
Figure 22: Drug assessment summary of atezolizumab for triple-negative breast cancer
Figure 23: Drug assessment summary of atezolizumab for triple-negative breast cancer

List of Tables
Table 1: Tecentriq drug profile
Table 2: Tecentriq Phase III trials in prostate cancer
Table 3: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 4: Tecentriq drug profile
Table 5: Tecentriq Phase III trial in colorectal cancer
Table 6: Tecentriq early-phase data in colorectal cancer
Table 7: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
Table 8: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016-25
Table 9: Tecentriq drug profile
Table 10: Tecentriq Phase III trials in ovarian cancer
Table 11: Overview of Phase I data for Tecentriq in ovarian cancer
Table 12: Tecentriq drug profile
Table 13: Tecentriq pivotal trial data in urothelial bladder cancer
Table 14: Tecentriq ongoing late-phase trials in urothelial bladder cancer
Table 15: Tecentriq drug profile
Table 16: Tecentriq Phase III trial in renal cell cancer
Table 17: Tecentriq drug profile
Table 18: Tecentriq Phase III trials in non-small cell lung cancer
Table 19: Tecentriq early-phase data in non-small cell lung cancer
Table 20: Atezolizumab drug profile
Table 21: Atezolizumab Phase III trial in triple-negative breast cancer
Table 22: Atezolizumab Phase Ib data in triple-negative breast cancer
Table 23: Atezolizumab Phase I data in triple-negative breast cancer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll